Abstract 1565P
Background
Germline polymorphisms may have an association with survival and response to chemotherapy. We examined the gene polymorphism data from the landmark OEO2 trial which compared chemotherapy plus surgery vs surgery alone in early oesophageal cancer. We reviewed common DNA repair genes polymorphisms and selected a subset that has been validated as predictors of survival or chemotherapy toxicity across different tumor types.
Methods
DNA formalin-fixed paraffin embedded normal tissue was available for 515/802 OEO2 patients and successfully extracted in 90% (464/515) of samples. Gene polymorphisms were investigated for GSTP1, TS 3’UTR, TS 5’UTR, OPRT, DYPD, ERCC1, ERCC2, XRCC1 using Sequenom or multiplex PCR and gel electrophoresis. We investigated these polymorphisms and their relationship with clinicopathological variables including overall survival (OS) and progression free survival (PFS).
Results
All patients with the ERCC1_rs116115 CT genotype had superior OS and PFS when compared to those with a non CT genotype, OS HR 0.790 95% CI 0.642-0.972 (p=0.026), PFS HR 0.80 95% CI 0.656-0.979 (p=0.03). When stratified into chemotherapy + surgery (C+S) vs surgery alone (S), OS for those in the C+S arm was statistically significantly better in the CT genotype (OS 1.975 vs 1.547 years p=0.047) (HR 0.744 95% CI 0.55-0.998 p=0.048). In the S arm there was no significant difference in OS in the CT vs non CT genotype (1.339 vs 1.258 years p=0.275) (HR=0.849 95%CI 0.633-1.140 p=0.276). Test of interaction between treatment groups and ERCC1 polymorphisms was not significant for OS (p=0.58) and PFS (p=0.17). In patients who received preoperative chemotherapy, those with ERCC1 CT genotype were more likely to have any response to chemotherapy (Mandard TRG 1-4) than patients with non CT genotypes (CT vs non CT, 63% vs. 37%, p=0.031).
Conclusions
Patients with ERCC1 CT genotype had superior OS and PFS when compared to those with non CT genotype. Patients with ERCC1 CT genotype receiving preoperative chemotherapy had a better response compared to those with non CT genotype. ERCC1 polymorphisms have prognostic implications and may serve as biomarkers for preoperative chemotherapy response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MRC medical research council.
Funding
CRUK.
Disclosure
D. Cunningham: Financial Interests, Institutional, Research Grant: Clovis, Eli Lilly, 4SC, Bayer, Celgene, NIHR EME, Roche; Non-Financial Interests, Institutional, Product Samples, Provision of investigational product for study: Leap; Non-Financial Interests, Institutional, Advisory Role: Ovibio. P. Tan: Financial Interests, Personal, Advisory Board, I am on the Venture Corp Council of Experts: Venture Corp; Financial Interests, Personal, Advisory Board, Advisory Board member for Riyadh Biotech City: Riyadh Biotech City; Financial Interests, Institutional, Full or part-time Employment, I am a Professor at Duke-NUS Medical School Singapore: Duke-NUS Medical School; Financial Interests, Institutional, Full or part-time Employment, I serve as the Executive Director of the Genome Institute of Singapore: Agency for Science, Technology and Research; Financial Interests, Institutional, Full or part-time Employment, I serve as the Executive Director of Precision Health Research Singapore under the Ministry of Health.: Precision Health Research Singapore; Financial Interests, Personal, Stocks/Shares, I own shares in Tempus Healthcare: Tempus Healthcare; Financial Interests, Personal, Stocks/Shares, Auristone is a start-up from the Agency of Science, Technology and Research focused on cancer epigenetics: Auristone Pte Ltd. R. Sundar: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas; Financial Interests, Personal, Invited Speaker: MSD, Eli Lilly, BMS, Roche, Taiho, AstraZeneca, DKSH, Ipsen; Financial Interests, Personal and Institutional, Local PI: MSD, Taiho, BMS, Novartis; Financial Interests, Personal, Stocks/Shares: Teladoc; Financial Interests, Institutional, Advisory Board: Paxman Coolers; Non-Financial Interests, Advisory Role: Paxman Coolers; Non-Financial Interests, Principal Investigator: MSD, Natera. All other authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21